Withania somnifera Reverses Transactive Response DNA Binding Protein 43 Proteinopathy in a Mouse Model of Amyotrophic Lateral Sclerosis/Frontotemporal Lobar Degeneration
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Abnormal cytoplasmic mislocalization of transactive response DNA binding protein 43 (TARDBP or TDP-43) in degenerating neurons is a hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U). Our previous work suggested that nuclear factor kappa B (NF-κB) may constitute a therapeutic target for TDP-43-mediated disease. Here, we investigated the effects of root extract of Withania somnifera (Ashwagandha), an herbal medicine with anti-inflammatory properties, in transgenic mice expressing a genomic fragment encoding human TDP-43 A315T mutant. Ashwagandha extract was administered orally to hTDP-43 A315T mice for a period of 8 weeks starting at 64 and 48 weeks of age for males and females, respectively. The treatment of hTDP-43 A315T mice ameliorated their motor performance on rotarod test and cognitive function assessed by the passive avoidance test. Microscopy examination of tissue samples revealed that Ashwagandha treatment of hTDP-43 A315T mice improved innervation at neuromuscular junctions, attenuated neuroinflammation, and reduced NF-κB activation. Remarkably, Ashwagandha treatment reversed the cytoplasmic mislocalization of hTDP-43 in spinal motor neurons and in brain cortical neurons of hTDP-43 A315T mice and it reduced hTDP-43 aggregation. In vitro evidence is presented that the neuronal rescue of TDP-43 mislocalization may be due to the indirect effect of factors released from microglial cells exposed to Ashwagandha. These results suggest that Ashwagandha and its constituents might represent promising therapeutics for TDP-43 proteinopathies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arai, T., Hasegawa, M., Akiyama, H., Ikeda, K., Nonaka, T., Mori, H., Mann, D., Tsuchiya, K., Yoshida, M., Hashizume, Y., et al. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.10.093 · Cited by 2,732
Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43
Polymenidou, M., Lagier-Tourenne, C., Hutt, K. R., Huelga, S. C., Moran, J., Liang, T. Y., Ling, S.-C., Sun, E., Wancewicz, E., Mazur, C., et al. (2011) · Nature Neuroscience · doi:10.1038/nn.2779 · Cited by 1,335
Mutations of optineurin in amyotrophic lateral sclerosis
Maruyama, H., Morino, H., Ito, H., Izumi, Y., Kato, H., Watanabe, Y., Kinoshita, Y., Kamada, M., Nodera, H., Suzuki, H., et al. (2010) · Nature · doi:10.1038/nature08971 · Cited by 1,265 · cited 1×
“which encodes a protein activating the suppressor of NF-κB [31]; 3) mutations in valosin-containing protein activates NF-κB signalling [32, 33]; 4) overt inflammation was present in mice deficient for progranulin, a negative regulator of NF-κB activity [34]; 5) p62 (SQSTM1) can be associated with”
BackgroundMicroglial priming in neurodegenerative disease
Perry, V. H., & Holmes, C. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.38 · Cited by 1,127
Astrocytes from familial and sporadic ALS patients are toxic to motor neurons
Haidet-Phillips, A. M., Hester, M. E., Miranda, C. J., Meyer, K., Braun, L., Frakes, A., Song, S., Likhite, S., Murtha, M. J., Foust, K. D., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1957 · Cited by 782 · cited 1×
“Astrocytes have been reported in multiple studies to be implicated in inducing motor neuron death [49, 50].”
Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration
Lee, E. B., Lee, V. M.-Y., & Trojanowski, J. Q. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3121 · Cited by 659 · cited 1×
“TDP-43 is a DNA/RNAbinding protein and it is involved in regulating RNA transcription, splicing, trafficking, and microRNA biogenesis [4].”
BackgroundMicroglia Induce Motor Neuron Death via the Classical NF-κB Pathway in Amyotrophic Lateral Sclerosis
Frakes, A. E., Ferraiuolo, L., Haidet-Phillips, A. M., Schmelzer, L., Braun, L., Miranda, C. J., Ladner, K. J., Bevan, A. K., Foust, K. D., Godbout, J. P., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.01.013 · Cited by 638 · cited 1×
“exacerbated inflammatory responses [35] and mutations in ALS/FTLD increase p62 levels [36]; 6) NF-kB signaling pathway is upregulated in ALS induced pluripotent stem cellderived motor neurons [37]; 7) ablation of NF-κB signaling in microglia extended survival of superoxide dismutase 1 mutant mice [38].”
BackgroundBarmada, S. J., Skibinski, G., Korb, E., Rao, E. J., Wu, J. Y., & Finkbeiner, S. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4988-09.2010 · Cited by 554
An Overview on Ashwagandha: A Rasayana (Rejuvenator) of Ayurveda
Singh, N., Bhalla, M., De Jager, P., & Gilca, M. (2011) · African Journal of Traditional, Complementary and Alternative Medicines · doi:10.4314/ajtcam.v8i5s.9 · Cited by 544 · cited 1×
“Withaferin A is a component of the plant Withania somnifera dunal [or Ashwagandha (ASH)], a perennial plant belonging to the family Solanaceae [20] that has been in use for the last 4000 years in traditional Indian medical system (Ayurveda).”
BackgroundNorden, D. M., Muccigrosso, M. M., & Godbout, J. P. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.10.028 · Cited by 413 · cited 1×
“In response to neurodegeneration or to accumulations of misfolded proteins, microglia can proliferate and adopt an activated state with secretion of several factors that may be either beneficial or detrimental to neurons [52, 53].”
BackgroundSehgal, N., Gupta, A., Valli, R. K., Joshi, S. D., Mills, J. T., Hamel, E., Khanna, P., Jain, S. C., Thakur, S. S., & Ravindranath, V. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112209109 · Cited by 390 · cited 1×
“burden in a mouse model of Alzheimer’s disease [56].”
BackgroundMutations in SQSTM1 encoding p62 in amyotrophic lateral sclerosis: genetics and neuropathology
Teyssou, E., Takeda, T., Lebon, V., Boillée, S., Doukouré, B., Bataillon, G., Sazdovitch, V., Cazeneuve, C., Meininger, V., LeGuern, E., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1090-0 · Cited by 241 · cited 1×
“exacerbated inflammatory responses [35] and mutations in ALS/FTLD increase p62 levels [36]; 6) NF-kB signaling pathway is upregulated in ALS induced pluripotent stem cellderived motor neurons [37]; 7) ablation of NF-κB signaling in microglia extended survival of superoxide dismutase 1 mutant mice [38].”
BackgroundCuster, S. K., Neumann, M., Lu, H., Wright, A. C., & Taylor, J. P. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq050 · Cited by 204 · cited 1×
“which encodes a protein activating the suppressor of NF-κB [31]; 3) mutations in valosin-containing protein activates NF-κB signalling [32, 33]; 4) overt inflammation was present in mice deficient for progranulin, a negative regulator of NF-κB activity [34]; 5) p62 (SQSTM1) can be associated with”
BackgroundEffects of Ashwagandha (Roots of Withania somnifera) on Neurodegenerative Diseases
Kuboyama, T., Tohda, C., & Komatsu, K. (2014) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b14-00022 · Cited by 127 · cited 1×
“The neuroprotective property of the plant extract or purified products from the plant has been demonstrated in multiple disease models such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and spinal cord injuries [23].”
BackgroundInflammation Induces TDP-43 Mislocalization and Aggregation
Correia, A. S., Patel, P., Dutta, K., & Julien, J.-P. (2015) · PLOS ONE · doi:10.1371/journal.pone.0140248 · Cited by 114
Self-citationDifferentiated NSC-34 motoneuron-like cells as experimental model for cholinergic neurodegeneration
Maier, O., Böhm, J., Dahm, M., Brück, S., Beyer, C., & Johann, S. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2013.03.008 · Cited by 108 · cited 2×
“Prior to experimentation, these cells were differentiated as per the published protocol [29].”
BackgroundMethodTohda, C., & Joyashiki, E. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00313.x · Cited by 62
Cited by
Paul, S., Chakraborty, S., Anand, U., Dey, S., Nandy, S., Ghorai, M., Saha, S. C., Patil, M. T., Kandimalla, R., Proćków, J., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112175 · Cited by 306
Natural Products as a Potential Modulator of Microglial Polarization in Neurodegenerative Diseases
Jin, X., Liu, M.-Y., Zhang, D.-F., Zhong, X., Du, K., Qian, P., Gao, H., & Wei, M.-J. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104253 · Cited by 109
Dutta, K., Patel, P., & Julien, J.-P. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2018.08.008 · Cited by 56
Self-citationMitigation of ALS Pathology by Neuron-Specific Inhibition of Nuclear Factor Kappa B Signaling
Dutta, K., Thammisetty, S. S., Boutej, H., Bareil, C., & Julien, J.-P. (2020) · The Journal of Neuroscience · doi:10.1523/jneurosci.0536-20.2020 · Cited by 55
“An involvement of NF-kB in ALS is further supported by the evidence that pharmacological inhibition of this pathway conferred beneficial effects in mouse models of ALS, including attenuation of TDP-43 pathology in motor neurons (Swarup et al., 2011b; Dutta et al., 2017).”
BackgroundMethodSelf-citation
Metadata
- Authors
- Dutta, K., Patel, P., Rahimian, R., Phaneuf, D., & Julien, J.-P.
- Venue
- Neurotherapeutics
- Publisher
- Elsevier BV
- Published
- 2017-04
- Volume
- 14
- Issue
- 2
- Pages
- 447-462
- ISSN
- 1878-7479 (ISSN-L)
- OpenAlex
- W2560539130
- Cited by
- 51
- References
- 17
- FWCI
- 3.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.